| Transactivation of the TPA-responsive element by the oncogenic C-erbB-2 protein is partly mediated by protein kinase C. | None |
| Multiparameter flow-cytometric quantitation of epidermal growth factor receptor and c-erbB-2 oncoprotein in normal and neoplastic tissues of the female genital tract. | None |
| Ligand-independent tyrosine phosphorylation of the receptor encoded by the c-neu oncogene. | None |
| The transmembrane domain of the oncogenic mutant ErbB-2 receptor: a structure obtained from site-specific infrared dichroism and molecular dynamics. | None |
| Rat monoclonal antibodies to the external domain of the product of the C-erbB-2 proto-oncogene. | None |
| Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation. | None |
| Oncogenic potential of erbB-2 in human mammary epithelial cells. | None |
| Expression of c-erbB-2 oncoprotein in mammary and extramammary Paget s disease. | None |
| The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. | None |
| Targeting the function of the HER2 oncogene in human cancer therapeutics. | None |
| Effects of fixative and fixation protocols on assessment of Her-2/neu oncogene amplification status by fluorescence in situ hybridization. | None |
| Microwave enhancement of CISH for HER2 oncogene. | None |
| Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study. | None |
| Ikkalpha is an important contributor to ErbB2-induced oncogenesis, providing signals that maintain mammary tumor-initiating cells. | None |
| HER2 gene amplification is a complex event: it includes coamplification of other, potentially oncogenic genes and facilitates the generation of additional genomic aberrations [review] | None |
| Giacomo Castelvetro s salads. Anti-HER2 oncogene nutraceuticals since the 17th century?. | None |
| CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability. | None |
| restricting CDC25A can limit tumorigenesis induced by the HER2/neu-RAS oncogenic pathway without compromising normal cell division or viability [review] | None |
| AIB1/SRC-3 is required for HER2/neu oncogenic activity and for the phosphorylation and activation of the HER2/neu receptor | None |
| EBNA1-NT may act as a repressor of the HER2/neu oncogene | None |